FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897984913> ?p ?o ?g. }

• W2897984913 endingPage "173" @default.
• W2897984913 startingPage "166" @default.
• W2897984913 abstract "Background and purpose The PET-boost randomized phase II trial (NCT01024829) investigated dose-escalation to the entire primary tumour or redistributed to regions of high pre-treatment FDG-uptake in inoperable non-small cell lung cancer (NSCLC) patients. We present a toxicity analysis of the 107 patients randomized in the study. Materials and methods Patients with stage II–III NSCLC were treated with an isotoxic integrated boost of ≥72 Gy in 24 fractions, with/without chemotherapy and strict dose limits. Toxicity was scored until death according to the CTCAEv3.0. Results 77 (72%) patients were treated with concurrent chemoradiotherapy. Acute and late ≥G3 occurred in 41% and 25%. For concurrent (C) and sequential or radiotherapy alone (S), the most common acute ≥G3 toxicities were: dysphagia in 14.3% (C) and 3.3% (S), dyspnoea in 2.6% (C) and 6.7% (S), pneumonitis in 0% (C) and 6.7% (S), cardiac toxicity in 6.5% (C) and 3.3% (S). Seventeen patients died of which in 13 patients a possible relation to treatment could not be excluded. In 10 of these 13 patients progressive disease was scored. Fatal pulmonary haemorrhages and oesophageal fistulae were observed in 9 patients. Conclusion Personalized dose-escalation in inoperable NSCLC patients results in higher acute and late toxicity compared to conventional chemoradiotherapy. The toxicity, however, was within the boundaries of the pre-defined stopping rules." @default.
• W2897984913 created "2018-10-26" @default.
• W2897984913 creator A5007540116 @default.
• W2897984913 creator A5007868555 @default.
• W2897984913 creator A5009910490 @default.
• W2897984913 creator A5026721265 @default.
• W2897984913 creator A5037246030 @default.
• W2897984913 creator A5049829317 @default.
• W2897984913 creator A5052958356 @default.
• W2897984913 creator A5057987192 @default.
• W2897984913 creator A5061784734 @default.
• W2897984913 creator A5072057503 @default.
• W2897984913 creator A5077313682 @default.
• W2897984913 creator A5081949115 @default.
• W2897984913 creator A5087851185 @default.
• W2897984913 date "2019-02-01" @default.
• W2897984913 modified "2023-10-06" @default.
• W2897984913 title "The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)" @default.
• W2897984913 cites W1968899146 @default.
• W2897984913 cites W1969939751 @default.
• W2897984913 cites W1982331996 @default.
• W2897984913 cites W1989783323 @default.
• W2897984913 cites W1990201709 @default.
• W2897984913 cites W1995308403 @default.
• W2897984913 cites W2003456733 @default.
• W2897984913 cites W2006531869 @default.
• W2897984913 cites W2013656320 @default.
• W2897984913 cites W2018728498 @default.
• W2897984913 cites W2022401781 @default.
• W2897984913 cites W2028760979 @default.
• W2897984913 cites W2033894528 @default.
• W2897984913 cites W2059589551 @default.
• W2897984913 cites W2065570319 @default.
• W2897984913 cites W2067643750 @default.
• W2897984913 cites W2073000887 @default.
• W2897984913 cites W2075577903 @default.
• W2897984913 cites W2085901994 @default.
• W2897984913 cites W2099382658 @default.
• W2897984913 cites W2104701073 @default.
• W2897984913 cites W2123507044 @default.
• W2897984913 cites W2137716692 @default.
• W2897984913 cites W2151507261 @default.
• W2897984913 cites W2159113158 @default.
• W2897984913 cites W2263280562 @default.
• W2897984913 cites W2282423929 @default.
• W2897984913 cites W2286769860 @default.
• W2897984913 cites W2312703485 @default.
• W2897984913 cites W2336177995 @default.
• W2897984913 cites W2416129168 @default.
• W2897984913 cites W2592779905 @default.
• W2897984913 cites W2595526561 @default.
• W2897984913 cites W2621243763 @default.
• W2897984913 cites W2766131025 @default.
• W2897984913 doi "https://doi.org/10.1016/j.radonc.2018.09.019" @default.
• W2897984913 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30327236" @default.
• W2897984913 hasPublicationYear "2019" @default.
• W2897984913 type Work @default.
• W2897984913 sameAs 2897984913 @default.
• W2897984913 citedByCount "55" @default.
• W2897984913 countsByYear W28979849132019 @default.
• W2897984913 countsByYear W28979849132020 @default.
• W2897984913 countsByYear W28979849132021 @default.
• W2897984913 countsByYear W28979849132022 @default.
• W2897984913 countsByYear W28979849132023 @default.
• W2897984913 crossrefType "journal-article" @default.
• W2897984913 hasAuthorship W2897984913A5007540116 @default.
• W2897984913 hasAuthorship W2897984913A5007868555 @default.
• W2897984913 hasAuthorship W2897984913A5009910490 @default.
• W2897984913 hasAuthorship W2897984913A5026721265 @default.
• W2897984913 hasAuthorship W2897984913A5037246030 @default.
• W2897984913 hasAuthorship W2897984913A5049829317 @default.
• W2897984913 hasAuthorship W2897984913A5052958356 @default.
• W2897984913 hasAuthorship W2897984913A5057987192 @default.
• W2897984913 hasAuthorship W2897984913A5061784734 @default.
• W2897984913 hasAuthorship W2897984913A5072057503 @default.
• W2897984913 hasAuthorship W2897984913A5077313682 @default.
• W2897984913 hasAuthorship W2897984913A5081949115 @default.
• W2897984913 hasAuthorship W2897984913A5087851185 @default.
• W2897984913 hasBestOaLocation W28979849132 @default.
• W2897984913 hasConcept C116263406 @default.
• W2897984913 hasConcept C126322002 @default.
• W2897984913 hasConcept C143998085 @default.
• W2897984913 hasConcept C2776256026 @default.
• W2897984913 hasConcept C2776694085 @default.
• W2897984913 hasConcept C2777714996 @default.
• W2897984913 hasConcept C2778424827 @default.
• W2897984913 hasConcept C2779524853 @default.
• W2897984913 hasConcept C2781047374 @default.
• W2897984913 hasConcept C29730261 @default.
• W2897984913 hasConcept C509974204 @default.
• W2897984913 hasConcept C71924100 @default.
• W2897984913 hasConcept C90924648 @default.
• W2897984913 hasConceptScore W2897984913C116263406 @default.
• W2897984913 hasConceptScore W2897984913C126322002 @default.
• W2897984913 hasConceptScore W2897984913C143998085 @default.
• W2897984913 hasConceptScore W2897984913C2776256026 @default.
• W2897984913 hasConceptScore W2897984913C2776694085 @default.
• W2897984913 hasConceptScore W2897984913C2777714996 @default.

• next